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Helicobacter pylori infection induces chronic inﬂammation which is characterized not only
by inﬁltrations of inﬂammatory cells such as neutrophils and CD4+ T cells, but also sig-
niﬁcant populations of regulatory T cells (Treg). These cells are important for disease
pathogenesis because they are believed to contribute to the persistence of the infection.
Despite encouraging results in animal models, the prospects for an effective H. pylori vac-
cine are currently poor because of generally disappointing results in preclinical and phase 1
trials. As a result, a current major focus of basic research on vaccination is to better under-
stand the mechanisms regulating the inﬂammatory response with the view it can inform
future vaccine design. Our studies in this area have focused on gastric CD4+ Treg in vacci-
nated mice, and raised the hypothesis that adipokines in particular leptin are involved the
establishment of a protective gastric immune response. Here we discuss the hypothesis
that vaccination deregulatesTreg responses in the gastric mucosa, and that this process is
mediated by leptin.We propose that reduced suppression permits a protective sub popula-
tion of H. pylori -speciﬁc CD4+T cells to exert protective effects, presumably via the gastric
epithelium. Evidence from the literature and experimental approaches will be discussed.
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INTRODUCTION
H. pylori INFECTION INDUCES BOTH A STRONG INFLAMMATORY
CD4+ T CELL AND CD4+ Treg RESPONSE
Helicobacter pylori chronically infects the mucus gel layer of the
human stomach. This pathogen is highly adapted to the gastric
niche and the natural immune response does not clear infection
(Blaser, 2004). Most cases of H. pylori gastritis are sub-clinical,
and the inﬂammation leads to symptomatic gastritis in only
about 10% of infected persons, the implications of asymptomatic
infections remain unknown (Robertson et al., 2003). H. pylori
pathogenicity is dependent on both host and bacterial factors and
the mechanisms are complex and remain to be explained clearly
(Blaser, 2004).
Helicobacter pylori gastritis is characterized by strong inﬁl-
trates of CD4+ T cells, Neutrophils and B cells (D’Elios et al.,
1997; Strömberg et al., 2003) in the gastric mucosa. When one
considers the high numbers of persons chronically infected with
H. pylori worldwide, and that a relatively low proportion of these
develop symptoms, it might be seen as circumstantial evidence
that this inﬂammation is under tight regulatory control. Stud-
ies in biopsies from infected patients and experimental animals
have supported the importance of suppressor or regulatory T cells
(Treg) (CD4+/CD25+/FoxP3+) in H. pylori pathogenesis. Indeed
relatively high numbers of H. pylori-speciﬁc Treg are present in the
stomach of asymptomatic H. pylori-infected patients (Lundgren
et al., 2003; Goll et al., 2007) and that these suppressed mem-
ory T cell function in vitro. Similarly, studies in experimentally
infected mice showed that Treg, suppressed proliferation of CD4+
T cells, and that this probably contributes to the persistence of
the pathogen (Raghavan and Holmgren, 2005; Rad et al., 2006).
In addition, these CD4+ Treg have been shown to be speciﬁc
for H. pylori antigens in humans (D’Elios et al., 1997) and mice
(Raghavan et al., 2004). Further, Enarsson et al. (2006) reported
antigen-speciﬁc functional Treg in the mucosa of patients with
gastric tumors, it is noteworthy that greater numbers of Treg
were detected in tumors as opposed to non-tumor tissue. In this
circumstance, Treg may suppress natural protective anti-tumor
mechanisms.
It is likely therefore that in most infected persons, H. pylori
gastritis is tightly controlled by a complex balance of pro-
inﬂammatory and suppressive T cells, and only when this balance
is shifted by other factors do overtly pathogenic mechanisms move
into action. The impact of these mechanisms is evident in the
prevalence and clinical signiﬁcance of gastric and duodenal ulcer
disease, and gastric cancer. Understanding the factors inﬂuencing
Treg function in the stomach will be one of the keys to progress in
therapy and vaccination against H. pylori.
GASTRIC Treg AS AN OBSTACLE TO VACCINATION
The reports of successful immunization in animal models lead to
early enthusiasm for a vaccine, and a variety of strategies, both oral
and parenteral have been shown to be effective at reducing, but in
general not completely clearing colonization (e.g., Aebischer et al.,
2008b; Müller and Solnick, 2011). While there are some reports
of sterilizing protection in mice (Kleanthous et al., 2001; Garhart
et al., 2002; Panthel et al., 2003b) and in the gerbil model (Jeremy
et al., 2006), the overwhelming majority of reports report 1–3 logs
reduction in colonization, but not clearance (reviewed in Zhang
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et al., 2011). Data from animal studies have showed that vaccine-
induced protection is accompanied by increases in gastritis in
vaccinated mice (Ferrero et al., 1994; Sutton et al., 2001; Garhart
et al., 2002), prompting the general belief that strong inﬂammation
is responsible for protection.
Early vaccine trials in human volunteers were disappointing
with regard to efﬁcacy, but showed that oral vaccination with
recombinant antigens was at least feasible (Kreiss et al., 1996; Kot-
loff et al., 2001). Limited immunogenicity and a relatively high
incidence of adverse effects were noted. Recent vaccine trials have
reported good immunogenicity, e.g., a mixed antigen vaccine
administered parenterally was immunogenic in H. pylori negative
volunteers (Malfertheiner et al., 2008). However to date there have
been only three trials in infected persons: two trials in H. pylori-
positive volunteers (Kreiss et al., 1996; Kotloff et al., 2001) and
one in prophylactically immunized and experimentally challenged
volunteers (Aebischer et al., 2008a). Although the vaccines were
reported as safe, signiﬁcant, if minor adverse effects were noted in
all studies, and only very limited evidence of protective effects was
obtained.
The impetus for vaccine development was lost because of the
generally discouraging results discussed above. Progress in our
understanding of the regulation of gastric inﬂammation, and pre
clinical testing of new antigen combinations and adjuvant formu-
lations are now a major focus. Questions have also been raised
as to whether vaccination is even feasible, and indeed the obsta-
cles are seemingly great. Given that the local gastric inﬂammatory
response in natural infection is apparently so tightly regulated, a
successful therapeutic vaccination strategy would need to over-
come this regulation, without tipping the balance toward activat-
ing severe gastritis. Treg may not be a hindrance to prophylactic
vaccination, as they might not be expected to appear until several
weeks/months after infection. Both prophylactic and therapeutic
vaccination must also direct a protective response via the epithe-
lium to clear an essentially extra cellular,motile, luminal pathogen.
Interest in an H. pylori vaccine has been rekindled with reports
of increasing antibiotic resistance (particularly to metronidazole
and clarithromycin; Grahamet al., 2007).Vaccination experiments
in knock-out mouse strains showed that in the absence of func-
tional CD4+ T cells, vaccination was not protective (Ermak et al.,
1998; Pappo et al., 1999). In addition, adoptive transfer of T cells
(CD4+) from vaccinated mice conferred protection in H. pylori-
challenged recipients (Mohammadi et al., 1997; Lucas et al., 2001).
Although this model is not entirely straightforward and we have
been able to reproduce these results in C57BL/6 mice in inde-
pendent experiments in one laboratory but not after moving to
another (Walduck and Becher, unpublished observations). The
data from CD4-deﬁcient mice are most compelling and clearly
these cells are instrumental in mediating protection. On the
other hand, T cell driven immune responses are also implied in
induction of gastric neoplasia (Enarsson et al., 2006; Sayi et al.,
2009). Indeed Mueller et al. (2009) have shown evidence that the
protective and pathogenic effects of T cells may be inseparable.
Others have suggested that there may be phenotypically dif-
ferent sub-populations of CD4+ cells that have protective effects
(Blanchard et al., 2004; Walduck et al., 2004). Evidence to support
this will be discussed here.
With the importance of Treg in H. pylori gastritis in mind, and
the potential obstacles for vaccination, there is regrettably almost
no information from the published human vaccine trials to date on
the impact of vaccination on Treg. That Treg may not interfere with
prophylactic vaccination was supported by the report of Aebischer
et al. (2008a), where FoxP3 positive cells were only detected in
the mucosa in H. pylori-challenged volunteers after 3 months.
There was however no signiﬁcant effect of vaccination, at least
up to 3 months when the study ended (Aebischer et al., 2008a,
supplementary information).
Studies in animal models show signiﬁcant populations of
Treg in H. pylori-infected mice (Raghavan et al., 2004), includ-
ing in the stomach (Becher et al., 2010). Other studies showed
that depletion of Treg led to worsened gastritis (Kaparakis et al.,
2006). Depleting Treg would be expected to improve vaccine efﬁ-
cacy by permitting increased pro-inﬂammatory responses, and
this was reported by Zhang et al. (2008) who employed anti-
gen pulsed DCs for vaccination. There are no other published
reports of this phenomenon. There remain no published data
from vaccination studies employing the mouse strain developed
by Rudensky and colleagues (Kim et al., 2007) where depletion of
Treg can be selectively induced by injection of diphtheria toxin.
This model offers the best possibility to determine the role for Treg
in vivo.
It should, however, be noted that alongside the reports of
exacerbated gastritis in vaccinated mice, there are also numerous
reports of effective vaccination (1–3 logs reductions in colo-
nization) in other strains of mice, e.g., BALB/c, where gastritis
minimal, or undetected by traditional methods (Gómez-Duarte
et al., 1998; Lucas et al., 2001; Panthel et al., 2003a). This implies
that gastritis per se is not they key requirement for a protec-
tive response and that is the ﬁrst suggestion that small protective
sub-populations are present.
We have investigated CD4+ and CD4+ Treg function in vac-
cinated C57BL/6 mice and compared gastric inﬁltrates to those
in the circulation, spleen and lymph nodes. We found not only
increased numbers of CD4 in the stomachs of vaccinated mice (as
has been reported by others) but also decreased proportions of
the Treg sub-population of CD4+ cells in the stomach. These data
imply that vaccination reduced suppression of CD4+ T cell num-
bers and function, and predicts that these cells will have a higher
proliferative capacity. This was indeed observed in in vitro studies
(Becher et al., 2010).
The lack of requirement of antibody (Ermak et al., 1998) and
many inﬂammatory cytokines including IFNγ, for vaccine medi-
ated reductions in colonization, was unexpected in light of the
strong Th1 response induced both infection and vaccination
(reviewed inAebischer et al., 2008b). Gene expression studies were
an alternative attempt to identify new pathways and mechanisms
involved in protection (Mueller et al., 2003a,b; Rahn et al., 2004;
Walduck et al., 2004).
One of the novel signature genes identiﬁed in these stud-
ies was adipokines – a family of genes associated with fat cells
(Mueller et al., 2003a;Walduck et al., 2004). Adipokines are deﬁned
as cytokines secreted by adipose tissue, many of which have
endocrine activity. This group includes leptin, chemerin, resistin
which have pro-inﬂammatory activity, and adiponectin which has
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anti-inﬂammatory activity (La Cava and Matarese, 2004; Goralski
et al., 2007; Wilk et al., 2011).
A ROLE FOR LEPTIN IN REGULATING INFLAMMATION
Leptin (Ob – the obese gene) is an adipocytokine that links
nutrition with immunity. Adipokines are produced by mature
adipocytes and other cell types (e.g., T cells, Treg, epithelial cells;
Siegmund et al., 2002). Leptin (also known as Ob, the obese gene)
is the best-studied adipokine to date, and acts as a hormone that
regulates the perception of hunger, and therefore food and energy
intake (Fantuzzi, 2005). Leptin has since also been implied in cyto-
protection (Konturek et al., 2001), bone mass control (Elefteriou
et al., 2004), and immune functions (Lord et al., 1998; Fantuzzi
et al., 2005), including the effect of nutritional status on immune
dysfunction (Papathanassoglou et al., 2006).
The leptin receptor is a single transmembrane protein that is
similar in structure to the gp130 family of receptors. Binding of the
16-kDa leptin protein triggers the receptor to form homodimers
and induces signaling principally via the JAK/STAT pathway (La
Cava and Matarese, 2004; Figure 1).
Ob-Re binds leptin but has no intracellular domain and
although there is a report that it can initiate signaling, is thought
to act chieﬂy as a method of storing leptin and as such prevents
signaling and transport of leptin (Tu et al., 2010). Leptin receptor-
signaling deﬁcient mice are obese, and diabetic and display a
marked increase in the number and suppressive function of Treg
cells (Taleb et al., 2007). Leptin can also directly regulate Treg func-
tion by acting as a strong has a strong inhibitor of proliferation
(De Rosa et al., 2007).
Leptin also acts as a chemo-attractant for neutrophils and
macrophages (Montecucco et al., 2006; Gruen et al., 2007), these
cells are also present in high proportions in vaccinated stomachs
(Becher et al., 2010). Both macrophages and neutrophils are
thought to migrate in response to local leptin gradients in tissues.
FIGURE 1 | Structure of leptin receptor isoforms. Ob-Rb contains the
longest intracellular domain, which is crucial for leptin signaling. Ob-Ra,
Ob-Rc, and Ob-Rd contain only short cytoplasmic domains. Ob-Re is
truncated at position 830. Box 1 is a JAK docking site, boxes 2 and 3
are STAT docking sites. A point mutation at position 894 in the long
form of ObR in the db/db mouse renders it incapable of signaling.
The db/db mouse is a well-characterized model for type I diabetes
and these congenic mice have a single nucleotide mutation that
result in splicing of a non-functional version of the major signaling
isoform Ob-Rb.
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Interestingly, in vitro stimulation via the leptin receptor induced
migration, but not activation of neutrophils and rendered them
unresponsive to “classical chemotaxins” such as IL-8 (Montecucco
et al., 2006). Conversely, leptin stimulation induced migration
and activation (caused Ca2+ inﬂux), but did not interfere with
the ability of a macrophage cell line to respond to MCP-1
(Gruen et al., 2007).
LEPTIN RECEPTOR SIGNALING IS REQUIRED FOR
VACCINE-INDUCED PROTECTION
As part of the follow-up from gene expression studies, we tested
prophylactic vaccination in leptin receptor signaling deﬁcient
C57BLKS Cg Leprdb/db mice, and found that they were not pro-
tected by prophylactic vaccination (Wehrens et al., 2008). This was
in spite of developing (mild) gastritis and H. pylori-speciﬁc anti-
body. While the latter does not necessarily suggest a protective
response, it does indicate that the db/db mouse is immunocom-
petent. We hypothesized that leptin signaling was required, not
for mounting an H. pylori-speciﬁc response, but rather for trans-
mitting the protective “ message” from the mucosa to the gastric
epithelium.
Taken together with the evidence from the literature on
the inﬂuence of leptin signaling on Treg, macrophages, and
neutrophils, it seems feasible that leptin signalingmay also provide
a link between CD4+ function and protection in wild-type mice.
Based on the literature, and results of our own experimental data
discussed below, we proposed that leptin plays a key role in signaling
between protective T cells and gastric epithelium.
Hypothesis:
• That strong gastritis is not required for a protective immune
response in vaccination – a small sub-population with a
“protective” phenotype is sufﬁcient.
• That leptin signaling regulates CD4 cell function by interfering
with the function of Treg and inﬂammatory cells in the stomach.
The above hypotheses lead to the following predictions:
Successful vaccination will be observed in mouse strains/models
where gastritis is mild/undetectable.
BALB/c mice develop weak, or delayed gastritis after H. pylori
infection (Lee et al., 1997; Panthel et al., 2003b). After vaccination,
BALB/c mice develop increased (although mild) gastritis and are
protected to similar level as strains that develop strong gastritis
such as C57BL/6 (Gómez-Duarte et al., 1998; Koesling et al., 2001;
Panthel et al., 2003b; Walduck et al., 2004; Sutton et al., 2007). The
reduced gastritis observed in BALB/c mice might be expected to
be due to the Th2 bias and increased proportion of Treg found in
this strain (Sacks and Anderson, 2004), however, Kaparakis et al.
(2006) reported that depletion of Treg using anti-CD25 antibody
did not affect the intensity of gastritis, but the cytokine secretion
pattern. The use of anti-CD25 antibodies could also have depleted
other activated T cell populations and so the approach using spe-
ciﬁc in vivo depletion of Treg discussed above will be required to
clarify this question.
It is interesting to note that while CBA mice, which also develop
only mild gastritis, were protected by prophylactic vaccination,
therapeutic vaccination was ineffective (Sutton andWilson, 2004).
It would appear that additional genetic factors have a role to play
in gastric inﬂammation.
If a small sub-population is responsible for protection, then a
distinct phenotype of the protective will be recognizable, and small
numbers will be required for protection.
The microarray studies that display a speciﬁc gene expression
signature in protected mouse stomachs are indirectly suggestive
of this protective phenotype (Mueller et al., 2003b; Rahn et al.,
2004; Walduck et al., 2004). Further, analysis of gene expres-
sion patterns in biopsies from vaccinated human volunteers also
suggested a speciﬁc expression pattern and “T cell footprint”
(Aebischer et al., 2008a).
Analysis of gene expression patterns in lymphocyte sub-
populations isolated from gastric tissue of vaccinated and control
mice will provide more speciﬁc information on the “protective
program” induced in these cells.
Adoptive transfer studies where splenocytes or CD4+ cells from
vaccinated mice were transferred to recipients provided conﬁrma-
tion for the importance of these cells for protection, relatively
small numbers of cells are required to achieve this effect (in the
order of 5 × 106). These adoptively transferred cells do migrate to
the gastric mucosa and are detectable in small numbers (Aebischer
et al., 2008b; Becher and Walduck, unpublished observations).
That vaccination will be ineffective in the absence of leptin
As discussed above, we reported the requirement for functional
LepR signaling for protection in 2008 (Wehrens et al., 2008). The
result was observed using two different prophylactic vaccination
strategies.Wehave since also shown this in db/dbmice backcrossed
onto a C57BL/6 background (Becher et al., in preparation).
If our previous observations hold, then leptin will impact CD4+
T cells and Treg proliferation and function.
The ﬁrst suggestion for this comes from the analysis of gene
expression patterns in the stomachs of vaccinated and non-
protected db/db mice. For the most part, we observed the same
genes were expressed in protected wild-type as obese mice, but
interestingly, genes were more strongly up- or downregulated in
obese db/db mice (Wehrens et al., 2008). This is suggestive of a lack
of appropriate regulation or control of the inﬂammatory response
in the absence of leptin signaling. Our observation is also in keep-
ing with the reported role for LepR signaling in Treg function.
De Rosa et al. (2007) proposed that Treg control their own func-
tion in an autocrine fashion, by expressing both leptin and leptin
receptor.
Based on the results of our previous descriptive studies on local
gastric responses (Becher et al., 2010), we predicted that the role
for leptin would be in a local gastric signaling network. Consistent
with this proposal, we have detected both gastric epithelial cells
and inﬁltrating lymphocytes express leptin receptor in H. pylori-
infected mice (Figure 2).
As a result of studies in models of both autoimmune and
infection, leptin is now accepted to play an important role in reg-
ulating the Th1/Th2/Treg balance (Procaccini et al., 2012), and
in this manner to regulate disease. A number of recent pub-
lications point to the importance of leptin in Treg-associated
disease which may well be applicable to the H. pylori system. Treg
play an important role in the complex inﬂammatory response
in atherosclerosis (Gotsman et al., 2007). Huertas et al. (2012)
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FIGURE 2 | Both leptin and leptin receptor are expressed locally
in the gastric mucosa. Immunohistochemistry using speciﬁc antibodies,
detected with a Cy2 labeled secondary antibody. Both leptin (A) and
lepR (B) are expressed in the gastric mucosa of vaccinated mice at
day 21 post-challenge with H. pylori SS1. Mice were vaccinated
with recombinant S. typhimurium expressing H. pylori urease
as previously described (Becher et al., 2010). Original
magniﬁcation ×20.
reported that dysfunctional endothelial cells from idiopathic pul-
monary arterial hypertension (IPAH) patients produced increased
levels of leptin, and a higher proportion of their Treg expressed lep-
tin receptor. The authors hypothesize that leptin disregulates Treg
and contributes to disease (Huertas et al., 2012). In addition, stud-
ies in mouse models of atherosclerosis revealed a critical role for
leptin in the alteration of the regulatory immune response. Defec-
tive LepR signaling improved Treg, function and led to dramatic
decreased in lesion size (Taleb et al., 2007).
Given that leptin is ubiquitous in normal serum, in vitro studies
on CD4+ T cell and Treg function will not have addressed the
situation of limiting leptin concentration, this point has also been
raised by other authors (De Rosa et al., 2007). Available leptin
concentrations in the tissue may well be lower than in standard
tissue culture media. We are currently addressing this issue by
examining the proliferative and suppressive ability of H. pylori-
speciﬁc Treg under leptin-limiting conditions.
Because commercially available antibodies detect all receptor
isoforms, there is also little information on the expression of the
various isoforms of on immune cell populations. We speculate
that leptins’ inﬂuence on Treg, CD4 and neutrophil function is
orchestrated by expression of different receptor isoforms. Our
preliminary analyses using an RT-PCR approach on sorted cell
populations have shown that at least three different isoforms of
LepR are expressed by CD4+ cells alone (Figure 3). We anticipate
that further studies will reveal this repertoire may also be tissue-
speciﬁc.
It remains to be demonstrated whether leptin receptor expres-
sion at the level of lymphocytes (CD4+ T cells or Treg), or indeed
the gastric epithelium aremost important inmediating the protec-
tive effects of vaccination. It is conceivable that leptin secreted by
T cells may signal via LepR on gastric epithelial cells, and therefore
mediate a protective response (Figure 4). Alternatively, LepR sig-
naling onCD4+ Tcells and/orTreg may regulate inﬂammation and
therefore the protective response. We are currently investigating
these possibilities (Becher et al., in preparation). If these interac-
tions are shown to play a signiﬁcant role, it will be interesting to
determine the extent to which they interact with the previously
FIGURE 3 | LeptinR isoforms Ob-Rb, Rc, and Re by murine CD4+
T cells. Expression of leptinR isoforms by RT-PCR. CD4+ T cells were
isolated and puriﬁed by negative selection from the MLN of H. pylori
unvaccinated, infected female C57BL/6 mice. Equal amounts of
MLN cDNA were analyzed for expression of Ob-Rb (295 bp), Ob-Rc
(205 bp), and Ob-Re (257 bp, expression of Ob-Re is indicated with
an arrow head). Positive control HPRT (399 bp), no RT control
(control).
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FIGURE 4 | Possible role of leptin in inflammation and vaccine-induced
protection. In the vaccinated stomach, H. pylori challenge triggers CD4+ T
cells, neutrophils, and macrophages to inﬁltrate the mucosa, proportions of
Treg are reduced. Two possible mechanisms are proposed for the manner in
which leptin signaling is important for regulating this inﬂammation: (A) CD4+
T cells secrete leptin (black arrows), which acts as the message to stimulate
epithelial cells to facilitate protective responses. (B) Alternatively, CD4+ T
cells secrete leptin, which acts in an autocrine manner to stimulate their own
proliferation, and suppressTreg function. Leptin also affects macrophages and
neutrophil function, depending on expression of speciﬁc LepR isoforms. This
signaling induces secretion of other messages (gray arrow), which in turn
stimulate epithelial cells to facilitate protective responses.
demonstrated role for IL-17 in protection and inﬂammation in
H. pylori infection (Velin et al., 2009; Flach et al., 2011).
Our current studies are addressing a series of questions which
we believe will provide a “road map” for testing the hypothesis:
• Are the effects of leptin signaling mediated by direct action
on epithelial cells, or immune (bone marrow-derived) cells the
gastric mucosa?
• Does local leptin production can affect T cell and Treg function
in the mucosa? Are the effects on these cells direct or indirect?
Or is systemically produced leptin required?
• And ﬁnally, and more speculatively is there a relationship
between the effects of IL-17 and leptin in the stomach? It is pos-
sible that these mediators are part of the same local “program,”
or that their effects are speciﬁc and sequential.
In conclusion, we have provided evidence for the proposal
that leptin has an important role in regulating Treg and CD4+
T cell function in the gastric tissue. More detailed studies testing
these hypotheses are underway and will ultimately clarify this.
In the interim, we believe at least that this adipokine should
be considered as an important player in the control of gastric
inﬂammation.
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